VTGNNasdaqPharmaceutical PreparationsFiscal year ends March 31
Vistagen Therapeutics, Inc.
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.20+0.00 (+1.55%)
Close on Oct 19, 2026
- Market cap
- $8.73M
- P/E (TTM)
- –
- Dividend yield
- –
Vistagen Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Vistagen Therapeutics | Industry median |
|---|---|---|
| Market Cap | $9.01M | $164.85M |
| Enterprise Value | -$22.69M | $87.06M |
| PS Ratio | 3.60 | 3.60 |
| PB Ratio | 0.37 | 2.03 |
| P/TBV Ratio | 0.37 | 2.31 |
Enterprise value
| Measure | Vistagen Therapeutics | Industry median |
|---|---|---|
| EV / Sales | -9.07 | 2.43 |
Income (trailing twelve months)
| Measure | Vistagen Therapeutics | Industry median |
|---|---|---|
| Revenue | $2.50M | $57.94M |
| Operating Income | -$69.66M | -$21.44M |
| Pretax Income | -$67.61M | -$14.45M |
| Net Income | -$67.62M | -$22.46M |
| EBITDA | -$69.45M | -$16.91M |
| EPS (Diluted) | -$1.67 | -$0.83 |
Margins
| Measure | Vistagen Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -2784.3% | -44.5% |
| Pretax Margin | -2702.4% | -13.0% |
| Profit Margin | -2702.6% | -39.2% |
| EBITDA Margin | -2775.9% | -31.3% |
Returns
| Measure | Vistagen Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -166.5% | -53.1% |
| Return on Assets (ROA) | -129.2% | -41.0% |
| Return on Capital Employed (ROCE) | -283.8% | -37.8% |
Growth
| Measure | Vistagen Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (5Y CAGR) | 3.10% | 6.42% |
Balance sheet
| Measure | Vistagen Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $31.70M | $62.42M |
| Net Cash (Debt) | $31.70M | $15.68M |
| Net Cash Per Share | $0.71 | $0.66 |
| Equity (Book Value) | $24.48M | $48.79M |
| Book Value Per Share | $0.55 | $1.36 |
| Tangible Book Value | $24.48M | $23.06M |
| Working Capital | $23.12M | $75.77M |
Financial position
| Measure | Vistagen Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 3.07 | 3.30 |
| Quick Ratio | 2.83 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Vistagen Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$62.30M | -$12.35M |
Efficiency
| Measure | Vistagen Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.05 | 0.38 |
| Revenue Per Employee | $61.02K | $398.96K |
| Profits Per Employee | -$1.65M | -$703.34K |
| Employee Count | 41 | 74 |
Dividends and yields
| Measure | Vistagen Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -750.3% | -22.7% |
Shares
| Measure | Vistagen Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 44,376,900 | 58,179,650 |
| Shares Change (YoY) | 30.8% | 11.1% |
| Float | 44,144,800 | 49,173,100 |
| Shares Held by Insiders | 0.52% | 11.6% |
| Shares Held by Institutions | 26.5% | 59.4% |
Taxes
| Measure | Vistagen Therapeutics | Industry median |
|---|---|---|
| Income Tax | $7.00K | $91.50K |
Scores
| Measure | Vistagen Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -24.32 | -0.24 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Vistagen Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.